 |
|
New report: The truth about drug innovation
June 25, 2008New York, NY: A new report co-authored by Manhattan Institute senior fellow Benjamin Zycher, and Joseph DiMasi, and Christopher-Paul Milne, researchers from the Tufts Center for the Study of Drug Development, examines case histories for thirty-five important pharmaceutical innovations. Skeptics of the private industry assert that the development of new medicines is most attributable to publicly funded sources.
As Marcia Angell, former editor-in-chief of The New England Journal of Medicine, remarked during an interview with PBS News : "Innovation comes mainly from NIH-supported research in academic medical centers. The drug companies do almost no innovation."
In this new study, the authors debunk this assertion and argue that the private sector plays a critical role in drug development.
Key findings include:
* NIH-sponsored research tends to be concentrated on the basic science of disease biology, biochemistry, and disease processes, the goal of which is to identify biologic targets that might prove vulnerable to drugs yet to be developed.
* Private sector contributions are weighted heavily toward the applied science of discovering ways to pursue treatments and cures for adverse medical conditions.
The authors conclude that NIH-sponsored and private-sector drug research are complementary to one another and are equally necessary in order to provide patients with better care and treatment.
Tufts University, Health Sciences
Key findings include:
* NIH-sponsored research tends to be concentrated on the basic science of disease biology, biochemistry, and disease processes, the goal of which is to identify biologic targets that might prove vulnerable to drugs yet to be developed.
* Private sector contributions are weighted heavily toward the applied science of discovering ways to pursue treatments and cures for adverse medical conditions.
The authors conclude that NIH-sponsored and private-sector drug research are complementary to one another and are equally necessary in order to provide patients with better care and treatment.
Tufts University, Health Sciences
Drug Development News and Current Drug Development Events RSSTAU Researchers Create New Stem Cell Screening Tool
Stem cell research is the next great leap in medicine. In the future, new tissue grown in a laboratory could replace a failing heart, or new cells take the place of damaged cells in the brain.
Study: Delaying evolution of drug resistance in malaria parasite possible
There's no magic bullet for wiping out malaria, but a new study offers strong support for a method that effectively delays the evolution of drug resistance in malaria parasites, a University of Florida researcher says.
Atomic structure of the mammalian 'fatty acid factory' determined
Mammalian fatty acid synthase is one of the most complex molecular synthetic machines in human cells. It is also a promising target for the development of anti-cancer and anti-obesity drugs and the treatment of metabolic disorders.
Anti-Cancer Flower Power
Could a substance from the jasmine flower hold the key to an effective new therapy to treat cancer?
Research exposes new target for malaria drugs
The malaria parasite has waged a successful guerrilla war against the human immune system for eons, but a study in this week's Journal of Biological Chemistry has exposed one of the tricks malaria uses to hide from the immune proteins, which may aid in future drug development.
International panel updates treatment guidelines for HIV infection
An evaluation of recent data has led to an update in the guidelines and recommendations for antiretroviral treatment of adult human immunodeficiency virus (HIV) infection, according to an article in the August 6 issue of JAMA, a theme issue on HIV/AIDS.
N.Y. Research Team Discovers How Antidepressants and Cocaine Interact with Brain Cell Targets
In a first, scientists from Weill Cornell Medical College and Columbia University Medical Center have described the specifics of how brain cells process antidepressant drugs, cocaine and amphetamines. These novel findings could prove useful in the development of more targeted medication therapies for a host of psychiatric diseases, most notably in the area of addiction.
Vitamin A pushes breast cancer to form blood vessel cells
Researchers at Georgetown University Medical Center have discovered that vitamin A, when applied to breast cancer cells, turns on genes that can push stem cells embedded in a tumor to morph into endothelial cells. These cells can then build blood vessels to link up to the body's blood supply, promoting further tumor growth.
Fruit fly gene study could yield new flu treatments
As they design new drugs to fight off influenza, scientists may not need to attack the virus directly. Instead, they may be able to stave off infection by targeting one of more than 100 proteins inside host cells on which the virus depends.
Schizophrenia linked to dysfunction in molecular brain pathway activated by marijuana
Alterations in a molecular brain pathway activated by marijuana may contribute to the cognitive symptoms of schizophrenia, according to a report in the July issue of Archives of General Psychiatry, one of the JAMA/Archives journals.
More Drug Development News Articles
 | Drug-like Properties: Concepts, Structure Design and Methods: from ADME to Toxicity Optimization by Edward Kerns, Li Di Of the thousands of novel compounds that a drug discovery project team invents and that bind to the therapeutic target, typically only a fraction of these have sufficient ADME/Tox properties to become a drug product. Understanding ADME/Tox is critical for all drug researchers, owing to its increasing importance in advancing high quality candidates to clinical studies and the processes of drug... |
 | Career Opportunities in Biotechnology and Drug Development by Toby Freedman As the world of biotechnology has grown in leaps and bounds, so too have the career opportunities. But the choices can be daunting. What types of jobs are available? How do you get your foot in the door? What will your job entail if you become a "Preclinical Project Manager" or a "Process Scientist"? What s the difference between biotech and pharma?Career Opportunities in Biotechnology and Drug... |
 | Development of Fda-Regulated Medical Products: Prescription Drugs, Biologics, and Medical Devices by Elaine Whitmore There have been revolutionary changes to the classification and regulation of prescription drugs, biologics, and medical devices since the previous edition of this book was published in 1997 under the title Product Development Planning for Health Care Products Regulated by the FDA. The revised book includes: a review of the significant changes within the FDA that affect the requirements and... |
 | Drugs-From Discovery to Approval by Rick Ng Statistics show that out of five thousand compounds with initial promise, five will go into human clinical trials, and only one will become an approved drug. This tiny fraction illustrates the huge complexities involved in bringing a drug to market, a process that brings together scientific research, medical ethics, business, and various regulatory agencies. Drugs-From Discovery to Approval... |
 | The Plug-In Drug: Television, Computers, and Family Life by Marie Winn In The Plug-In Drug, Marie Winn demonstrates "with devastating persuasiveness" (The Washington Post) that television has a negative impact on child development, school achievement, and family life. But rather than focusing on program improvement as a solution, Winn proposes that the problem lies within the seductive act of TV watching itself. Extensive TV watching alters children's relations with... |
 | The Myth of the A.D.D Child:50 Ways to Improve Your Child's Behavior and Attention Span Without Drugs, Labels, or Coercion by Thomas Armstrong |
 | Strong Medicine: Creating Incentives for Pharmaceutical Research on Neglected Diseases by Michael Kremer, Rachel Glennerster Millions of people in the third world die from diseases that are rare in the first world--diseases like malaria, tuberculosis, and schistosomiasis. AIDS, which is now usually treated in rich countries, still ravages the world's poor. Vaccines offer the best hope for controlling these diseases and could dramatically improve health in poor countries. But developers have little incentive to... |
 | My Feet Aren't Ugly!: A Girl's Guide to Loving Herself from the Inside Out by Debra Beck Do you sometimes feel like other girls are prettier, more trendy, or more popular than you? Do you ever feel bad about yourself? In this funny, honest book, teen expert and mentor Debra Beck provides in-depth examples and exercises to develop the tools you need for self-confidence. Learn how to have fulfilling relationships, make good decisions for yourself, respect yourself and others, and... |
 | Illegal Drugs, Economy, and Society in the Andes (Woodrow Wilson Center Press) by Francisco E. Thoumi Some countries develop illegal drugs industries, and others do not. Discerning the distinguishing characteristics -- social, economic, and political -- of countries with these industries forms the subject of this sophisticated and humane study.The author, Francisco E. Thoumi, though trained as an economist, rejects simplistic economic solutions as well as simplistic moral ones as he addresses the... |
 | Poison Pills: The Untold Story of the Vioxx Drug Scandal by Tom Nesi To the millions of Americans who suffer from chronic pain and arthritis, Vioxx seemed like a miracle. One of the most widely promoted and prescribed pain medications in the world -- used by more than twenty million people -- it was endorsed by the medical establishment and celebrities such as Olympic champion figure skater Dorothy Hamill. With annual sales of $2.5 billion, Vioxx became a... |
| © 2008 BrightSurf.com |